Your browser doesn't support javascript.
loading
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
Vacca, Michele; Kamzolas, Ioannis; Harder, Lea Mørch; Oakley, Fiona; Trautwein, Christian; Hatting, Maximilian; Ross, Trenton; Bernardo, Barbara; Oldenburger, Anouk; Hjuler, Sara Toftegaard; Ksiazek, Iwona; Lindén, Daniel; Schuppan, Detlef; Rodriguez-Cuenca, Sergio; Tonini, Maria Manuela; Castañeda, Tamara R; Kannt, Aimo; Rodrigues, Cecília M P; Cockell, Simon; Govaere, Olivier; Daly, Ann K; Allison, Michael; Honnens de Lichtenberg, Kristian; Kim, Yong Ook; Lindblom, Anna; Oldham, Stephanie; Andréasson, Anne-Christine; Schlerman, Franklin; Marioneaux, Jonathon; Sanyal, Arun; Afonso, Marta B; Younes, Ramy; Amano, Yuichiro; Friedman, Scott L; Wang, Shuang; Bhattacharya, Dipankar; Simon, Eric; Paradis, Valérie; Burt, Alastair; Grypari, Ioanna Maria; Davies, Susan; Driessen, Ann; Yashiro, Hiroaki; Pors, Susanne; Worm Andersen, Maja; Feigh, Michael; Yunis, Carla; Bedossa, Pierre; Stewart, Michelle; Cater, Heather L.
Afiliação
  • Vacca M; TVP Lab, WT/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK. michele.vacca@uniba.it.
  • Kamzolas I; Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy. michele.vacca@uniba.it.
  • Harder LM; Laboratory of Liver Metabolism and MASLD, Roger Williams Institute of Hepatology, London, UK. michele.vacca@uniba.it.
  • Oakley F; TVP Lab, WT/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Trautwein C; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, UK.
  • Hatting M; Research and Early Development, Novo Nordisk A/S, Måløv, Copenhagen, Denmark.
  • Ross T; Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Bernardo B; Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
  • Oldenburger A; Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
  • Hjuler ST; Internal Medicine research Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, USA.
  • Ksiazek I; Internal Medicine research Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, USA.
  • Lindén D; CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
  • Schuppan D; Research and Early Development, Novo Nordisk A/S, Måløv, Copenhagen, Denmark.
  • Rodriguez-Cuenca S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Tonini MM; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gothenburg, Sweden.
  • Castañeda TR; Division of Endocrinology, Department of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Kannt A; Institute of Translational Immunology and Research Center for Immunotherapy, Johannes Gutenberg University Medical Center, Mainz, Germany.
  • Rodrigues CMP; TVP Lab, WT/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Cockell S; Luxembourg Institute of Health, Translational Medicine Operations Hub, Dudelange, Luxembourg.
  • Govaere O; R&D Diabetes & Portfolio Innovation and Excellence, Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt, Germany.
  • Daly AK; R&D Diabetes, Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt, Germany.
  • Allison M; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Innovation Center TheraNova and Goethe University, Frankfurt, Germany.
  • Honnens de Lichtenberg K; Research Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
  • Kim YO; Bioinformatics Support Unit, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Lindblom A; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Oldham S; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Andréasson AC; Liver Unit, Cambridge University Hospitals NHS Foundation Trust & Cambridge NIHR Biomedical Research Centre, Cambridge, UK.
  • Schlerman F; Research and Early Development, Novo Nordisk A/S, Måløv, Copenhagen, Denmark.
  • Marioneaux J; Institute of Translational Immunology and Research Center for Immunotherapy, Johannes Gutenberg University Medical Center, Mainz, Germany.
  • Sanyal A; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gothenburg, Sweden.
  • Afonso MB; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gaithersburg, MD, USA.
  • Younes R; Bioscience Cardiovascular, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gothenburg, Sweden.
  • Amano Y; Inflammation and Immunology Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, USA.
  • Friedman SL; Fleur De Lis Holdings 10201 Dakins Dr. Richmond, Richmond, VA, USA.
  • Wang S; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
  • Bhattacharya D; Research Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
  • Simon E; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Paradis V; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Burt A; Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Grypari IM; Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Davies S; Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Driessen A; Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Yashiro H; Global Computational Biology and Digital Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
  • Pors S; Department of Imaging and Pathology, Université Paris Diderot and Hôpital Beaujon, Paris, France.
  • Worm Andersen M; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Feigh M; Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
  • Yunis C; Department of Pathology, Aretaeion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Bedossa P; Department of Cellular Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Stewart M; Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
  • Cater HL; Department of Molecular Imaging, Pathology, Radiotherapy, Oncology. Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
Nat Metab ; 6(6): 1178-1196, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38867022
ABSTRACT
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD 'human proximity score' to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that Western diets align closely with human MASH; high cholesterol content, extended study duration and/or genetic manipulation of disease-promoting pathways are required to intensify liver damage and accelerate significant (F2+) fibrosis development. Choline-deficient models rapidly induce MASH-fibrosis while showing relatively poor translatability. Our ranking of commonly used MASLD models, based on their proximity to human MASLD, helps with the selection of appropriate in vivo models to accelerate preclinical research.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Modelos Animais de Doenças / Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Modelos Animais de Doenças / Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2024 Tipo de documento: Article